Tango Therapeutics, Inc.
TNGX
शेयरों में रैंक
#4545
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
शेयर मूल्य
$27.18
अंतिम समन्वयन: 2026-07-31
मार्केट कैप
$3.38B
बदलाव (1 दिन)
-1.41%
बदलाव (1 वर्ष)
202.34%
देश
US
व्यापार Tango Therapeutics, Inc. (TNGX)
श्रेणी
Healthcare
Tango Therapeutics, Inc. (TNGX) के लिए P/S अनुपात
October 2026 को P/S अनुपात TTM: 67.14
Tango Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/S अनुपात (TTM) 67.14 है। 2023 के अंत में, कंपनी का P/S अनुपात 25.63 था।
Tango Therapeutics, Inc. के लिए 2019 से 2026 तक P/S अनुपात का इतिहास
हर वर्ष के अंत में P/S अनुपात
| वर्ष | P/S अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 67.14 | 737.15% |
| 2024 | 8.02 | -68.70% |
| 2023 | 25.63 | 0.08% |
| 2022 | 25.61 | 39.62% |
| 2021 | 18.34 | -61.56% |
| 2020 | 47.71 | 1,179.46% |
| 2019 | 3.73 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/S अनुपात
| कंपनी | P/S अनुपात | P/S अनुपात में अंतर | देश |
|---|---|---|---|
| 10.02 | -85.07% |
US
|
|
| 40.55 | -39.60% |
US
|
|
| 3.96 | -94.10% |
AU
|
|
| 10.15 | -84.89% |
NL
|
|
| - | - |
CH
|
